I completely agree with you it's not a balanced post as you can...

I completely agree with you it's not a balanced post as you can see my sentiment is buy; therefore my bias obviously tilted towards the positive side. However, i disagree to accept that i'm cherry picking facts and projecting my wishful thinking. You mention HF trial not being stopped by the FDA during interim analysis for signs of overwhelming efficacy. Are you implying that failing to show overwhelming efficacy means; it will also fail to achieve primary endpoints that FDA has set for regulatory approval?  I think you have to understand the concept of unmet needs. These people don't have any treatment options and morbidity rate is very higher. Hospitalizations rate is higher. If MSB achieve primary endpoints as well as secondary endpoints for ischemia heart failure patients-these are very sick patients, than approval is likely. I still don't understand why majority of us are fixated on setting high bar of expectations for every MSB treatment effectiveness disregarding the need of patients. Expectations that somehow weaning LVAD is more important than GI bleeding and Hospitalizations because we expected that; doesn't matter what medical researcher and scientist say about that. Expectations that HF trail will achieve overwhelming efficacy and trial will be stopped and will move towards the process of regulatory approval;failing to understand the gravity of their sickness ; rehospitalizations cost, achieving Primary endpoints  for regulatory approval. Once again i kindly advise you to go through FDA websites and see regulatory approval framework and how treatment for unmet needs for devastating indications is viewed by FDA. 

Don't you think if data for 526 patients indicates that primary and secondary endpoints is achieved along with hospitalizations than what you make of it? If Data monitoring committee observed data on 86% of sample and advised to continue then. Doesn't it mean anything to you? Putting labels on one's opinion is easy than going through painstaking process of counter attacking with facts. If you tell me how failing to achieve overwhelming efficacy hinders MSB FDA regulatory approval, then i would accept that  my thinking is wishful and you are more realist than me.